Shire Pharmaceuticals Group Plc
Shire Announces Top-Line Results for Phase 2 Trial of SHP607 in Extremely Premature Infants
Lexington, Massachusetts (ots/PRNewswire) - - Top-line SHP607 study results in extremely premature infants showed no impact on primary endpoint of reducing the severity of Retinopathy of Prematurity - Top-line analysis of secondary endpoints showed clinically relevant effects on severe complications related to lung and brain damage - These data support further ...